Meeting
2024 ASCO Annual Meeting
H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).
Presenter
Dejan Juric, MD
Harvard Medical School
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT04288089
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 1051)
DOI
10.1200/JCO.2024.42.16_suppl.1051
Abstract #
1051
Poster Bd #
29
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).
Speaker: Erika P. Hamilton, MD
Videos & Slides
2023 ASCO Annual Meeting
Neoadjuvant giredestrant + palbociclib (P) vs. anastrozole (A) + P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2– eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study.
Speaker: Yeon Hee Park, MD, PhD
Videos & Slides
2021 ASCO Annual Meeting
Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
Speaker: Erika P. Hamilton, MD
Videos & Slides
2024 ASCO Annual Meeting
Racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer.
Speaker: Emily L Podany, MD